Cagrilintide

Buy Cagrilintide Online

Cagrilintide is a long-acting amylin analogue developed to influence appetite, satiety, and energy intake. Clinical research has demonstrated meaningful body-weight reductions and has also investigated its use alongside GLP-1 receptor agonists.

Product Information

Cagrilintide acts through amylin-related pathways involved in satiety and food intake. In clinical research, once-weekly cagrilintide has produced dose-dependent reductions in body weight, while combination studies have examined complementary GLP-1 and amylin activity.

How It Works

Cagrilintide activates amylin-associated signaling that helps regulate appetite and food intake. Its long-acting design allows the pathway to be stimulated over an extended period following administration.

Potential Benefits

1. Appetite & Satiety Support

Amylin signaling contributes to feelings of fullness and regulation of food intake. Cagrilintide has been studied specifically for its ability to influence these pathways over an extended period.

2. Body-Weight Reduction

Phase 2 clinical research demonstrated dose-dependent weight reduction with once-weekly cagrilintide. This has made body-weight management one of its central areas of clinical investigation.

3. Complementary Metabolic Activity

Cagrilintide can be combined mechanistically with GLP-1 receptor agonism because the two pathways regulate appetite through different but complementary mechanisms.

4. Glycemic & Metabolic Research

Clinical studies of cagrilintide-containing regimens have evaluated changes in body weight, HbA1c, glucose measures, and other metabolic outcomes. This gives the peptide relevance beyond appetite alone.

Dosage

Clinical trials have studied once-weekly cagrilintide doses ranging from approximately 0.3 mg to 4.5 mg, generally with dose escalation. These are study protocols rather than individualized dosing instructions, and combination formulations can have substantially different dosing requirements.

Side Effects

The most commonly reported adverse effects include nausea, vomiting, diarrhea, constipation, abdominal discomfort, and decreased appetite. Gastrointestinal effects are particularly relevant during dose escalation.

References

1. Lau DCW, Erichsen L, Francisco AM, et al. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. The Lancet. 2021;398(10317):2160-2172. PMID: 34798060. PubMed
2. Frias JP, Bajaj H, Dalskov SM, et al. Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2). Lancet Diabetes & Endocrinology. 2026. PMID: 42251859. PubMed

BehemothLabz does not sell this product. Purchase links on this page may direct you to third-party suppliers through affiliate links.

Please click here to see how purchases actually work on this site.